Rocket Lab's 95% Upside Is a Target Already Visited, and Abandoned

Rocket Lab has already been to the address your "95% upside" headline points at, and it left with a 55% loss of market value on the way home. The shares that closed near $64 today, a $39 billion company, spent part of this year at $151. The destination of the bullish target is not undiscovered territory. It is the exact neighborhood the stock has already visited and abandoned.

So the useful question is not whether Rocket Lab could rise 95% from here. Anything can, given enough catalysts and a willing multiple. The question is what would have to be true, in what order, for it to get there again — and which of those truths the market just decided it no longer believes.

The 95% is a crowd figure, not a forecast

Strip the headline to its skeleton and the number is a consensus artifact. Wall Street's mean price target sits near $113, individual estimates run to $150, and a widely circulated discounted-cash-flow model arrived at about $117. From the current $64, those cluster around the "roughly double" neighborhood that a 95% claim describes.

That is a betting line, not a thesis. It says: if Rocket Lab executes as the majority already expects, the stock is worth roughly double. The market itself answered that question two quarters ago. RKLB traded to $151 on roughly the same fundamentals now on the table — a $2.36 billion backlog, fast-growing revenue, government launch wins — and then the sellers took over, halving the entire enterprise on nothing more than a schedule slip and a reset of expectations. The 95% target is the same wager that already lost once, reissued without the receipt.

The machine is real; the price is the problem

None of this is an argument that Rocket Lab is a bad business. It is, by the numbers, a sharply improving one. Second-quarter revenue hit $234.1 million, up 62% year over year, powered by product revenue that nearly doubled to $181.3 million. First-half revenue of $434.4 million compares with $267.1 million a year earlier. Backlog is $2.36 billion, up 137%, with more than 90 launches contracted and new contracts flowing in after the quarter ended — including a $397 million U.S. Space Force program and a first government order for GEO satellites.

This is exactly the profile that makes beginners chase. But the price has already borrowed against all of it. Rocket Lab trades around 50 times trailing sales and roughly 40 times forward revenue, with no profit — second-quarter GAAP net loss was $49.3 million — and the company is financing its growth through an ~$8 billion acquisition of Iridium, paid in cash and newly issued stock, funded partly by a $3.6 billion bridge loan and a standing equity-drawdown facility. Dilution and leverage are the hidden taxes on the "double your money" headline that no price target footnote discloses.

Set the contract

Turn the headline into something scoreable. My version of the bet:

• Outcome: RKLB reaches $100 within 12 months — a softer, slower version of the 95% claim, chosen because the full double asks the market to re-extend the exact multiple that already broke.
• Deadline: September 2027, twelve months out.
• Implied market probability: low. The stock is down about 20% in the last month and has been falling for the year; the recent crash is the market pricing meaningful execution risk, not a rounding error.
• What I judge probable: materially lower than the target builders assume. The probability gap between the "double" and the going rate is the entire game.

The causal clock to $125

Three links must fire, in order, or the outcome does not.

One: Neutron flies and works. This is the hinge. The medium-lift rocket is the growth engine that justifies a 10-figure market cap on a loss-making company, and it has already slipped once — a propellant-tank failure in testing pushed the debut from mid-2026 to a fourth-quarter target, with a real risk the launch slides into 2027. No Neutron, no re-rating, no double. Every other target in the space is downstream of this.

Two: Iridium closes and delivers. The deal, expected to complete in mid-2027, adds Iridium's $871.7 million in 2025 revenue and its 57%-margin cash flow. But it halves the growth story's speed: Rocket Lab's $1 billion run-rate combined with Iridium's roughly $0.9 billion is suddenly a $2 billion company that paid $8 billion, in debt and stock, to get there. Acquisitive growth converted into EBITDA at a steep price is a different kind of "fast."

Three: the multiple holds. For the stock to double, revenue must keep compounding near 50% while investors keep assigning a premium multiple to a company that is now carrying debt and issuing stock to pay for it. That is the link most target-builders assume and most markets refuse. When the first two links take longer than the calendar assumed — as they already have — the third link snaps under its own weight.

Name the forced move, then the tripwire

The crowd holding the losing side of this bet is the one that bought the "double" narrative at $100, $120, and $150. They are not short; they are stuck. Their only path back to breakeven is the stock re-extending to where they entered, which means they need both Neutron and the Iridium close to succeed. That makes them unlikely to add at current levels, and it makes any further schedule slip or dilutive deal revision a catalyst for more forced selling into a thin bid.

Here is the first observable alarm: Neutron's delivery to the launch pad, targeted for the fourth quarter of 2026. If that date holds and the first flight is clean, the downside case loses its anchor. If it slips again — the second rocket date to move in a year — the "double" headline becomes a memory rather than a target. That is the tripwire, and it arrives before the 12-month verdict does.

Pay for the triggers, not the number. A 95% upside reading that depends on a schedule your own bus has already missed — once, with real money crossing the street — is a bet you should want to see working before you buy it.